Nanomedicine-nanoemulsion formulation improves safety and efficacy of the anti-cancer drug paclitaxel according to preclinical assessment

Journal of Nanoscience and Nanotechnology

Volumn 11, Issue 8, 2011, Pages 6642-6656

  Lee, King C ^a,b   Maturo, Claudia ^a   Rodriguez, Robert ^a   Nguyen, Hoang Lan ^c   Shorr, Robert ^a  

^a Department of Regulatory and Clinical Affairs   (United States)

^b QUINNIPIAC UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti cancer; EmPAC; Nanoemulsion; Nanotechnology; Paclitaxel; Taxol

Indexed keywords

ANTI-CANCER; EMPAC; NANOEMULSION; PACLITAXEL; TAXOL;

ANIMAL CELL CULTURE; ANIMALS; BIOLOGICAL ORGANS; DISEASES; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY; VEGETABLE OILS;

TUMORS;

ANTINEOPLASTIC AGENT; PACLITAXEL;

ANIMAL; ARTICLE; DRUG SCREENING; EMULSION; HUMAN; METABOLISM; MOUSE; NANOMEDICINE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; EMULSIONS; HUMANS; MICE; NANOMEDICINE; PACLITAXEL; TISSUE DISTRIBUTION;

EID: 84555205266     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2011.3928     Document Type: Conference Paper

References (46)

1. S. Surya Singh, J. Nanosci. Nanotechnol. 10, 7906 (2010).
2. E. Barbarese, S. Y. Ho, J. S. D'Arrigo, and R. H. Simon, J. Neuro-Oncol. 26, 25 (1995).
3. J. S. D'Arrigo, Drug News Persp. 4, 164 (1991).
4. J. S. D'Arrigo, R. H. Simon, and S. Y. Ho, J. Neuroimag. 1, 134 (1991).
5. J. S. D'Arrigo, S. Y. Ho, and R. H. Simon, Invest. Radiol. 28, 218 (1993).
6. S. Y. Ho, E. Barbarese, J. S. D'Arrigo, C. Smith, and R. H. Simon, Neurosurgery 40, 1260 (1997).
7. R. H. Simon, S. Y. Ho, C. R. Perkins, and J. S. D'Arrigo, Invest. Radiol. 27, 29 (1992).
8. R. H. Simon, S. Y. Ho, D. F. Uphoff, S. C. Lange, and J. S. D'Arrigo, Ultrasound Med. Biol. 19, 123 (1993).
9. A. K. Singla, A. Garg, and D. Aggarwal, Int. J. Pharm. 235, 179 (2002).
10. E. K. Rowinsky, L. A. Cazenave, and R. C. Donehover, J. Natl. Cancer Inst. 82, 1247 (1990).
11. M. C. Allwood and H. Martin, Int. J. Pharm. 127, 65 (1996).
12. D. Song, L. F. Hsu, and J. L. S. Au, J. Pharm. Sci. 85, 29 (1996).
13. Q. A. Xu, L. A. Trissel, and Y. Zhang, Int. J. Pharm. Compounding 2, 243 (1998).
14. W. N. Waugh, L. A. Trissel, and V. J. Stella, Am. J. Hosp. Pharm. 48, 1520 (1991).
15. R. B. Weiss, R. C. Donehower, P. H. Wiernik, T. Ohnuma, R. J. Gralla, D. L. Trump, J. R. Baker, D. A. Van Echo, D. D. Von Hoff, and B. Leyland-Jones, J. Clin. Oncol. 8, 1263 (1990).
16. E. K. Rowinsky and R. C. Donehower, Semin. Oncol. 20, 16 (1993).
17. G. J. Lesser, S. A. Grossman, S. Eller, and E. K. Rowinsky, Cancer Chemother. Pharmacol. 37, 173 (1995).
18. A. J. ten Tije, J. Verweij, W. J. Loos, and A. Sparreboom, Clin. Pharmacokinet. 42, 665 (2003).
19. H. H. Boer, C. M. Moorer-van Delft, L. J. Muller, B. Kiburg, J. B. Vermoken, and J. J. Heimans, J Neuro-Oncol. 25, 49 (1995).
20. A. J. Windebank, M. D. Blexrud, and P. C. de Groen, J. Pharmacol. Exp. Ther 268, 1051 (1994).
21. P. C. de Groen, A. J. Aksamit, J. Rakela, G. S. Forbes, and R. A. F. Krom, N. Engl. J. Med. 317, 861 (1987).
22. J. Liebmann, J. A. Cook, C. Lipschultz, D. Teague, J. Fisher, and J. B. Mitchell, Cancer Chemother. Pharmacol. 33, 331 (1994).
23. P. Nygren, K. Csoka, B. Jonson, H. Fridborg, H. Bergh, H. Hagberg, B. Glimeluis, O. Brodin, B. Tholander, A. Kreuger, G. Lonnerholm, A. Jackobsson, L. Olsen, J. Kristensen, and J. Larsson, Br. J. Cancer. 71, 478 (1995).
24. K. Csoka, S. Dhar, H. Fridborg, R. Larsson, and P. Nygren, Cancer 79, 1225 (1997).
25. D. B. Wilson, T. M. Beck, and C. A. Gundlach, Ann. Pharmacother. 31, 873 (1997).
26. J. Szebeni, C. R. Alving, S. Savay, Y. Barenholz, A. Priev, D. Danino, and Y. Talmon, Int. Immunopharmacology 1, 721 (2001).
27. A. Sparreboom, L. van Zuylen, E. Brouwer, W. J. Loors, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij, Cancer Research 59, 1454 (1999).
28. W. J. Loos, Szebeni, A. J. Ten Tije et al., Anticancer Drugs 13, 767 (2002).
29. G. Ellison, T. Klinowska, R. F. R. Westwood, E. Docter, T. French, and J. C. Fox, J Clin Pathol: Mol Pathol 55, 294 (2002).
30. D. T. Ross, U. Scherf, M. B. Eisen, C. M. Perou, C. Rees, P. Spellman, V. Iyer, S. S. Jeffrey, M. Van de Rijn, M. Waltham, A. Pergamenschikov, J. C. Lee, D. Lashkari, D. Shalon, T. G. Myers, J. N. Weinstein, D. Botstein, and P. O. Brown, Nat Genet. 24, 227 (2000).
31. J. S. Lee, K. Paull, A. Monks, C. Hose, A. Monks, M. Grever, A. T. Fojo, and S. E. Bates, Mol. Pharmacol. 46, 627 (1994).
32. M. Alvarez, K. Paull, A. Monks, C. Hose, J. S. Lee, J. Weinstein, M. Grever, S. Bates, and T Fojo, J. Clin. Invest. 95, 271 (1995).
33. W G. Harker and B. I. Sikic, Cancer Res. 45, 4091 (1985).
34. A. R. Thierry, D. Vige, S. S. Coughlin, J. A. Belli, A. Dritschilo, and A. Rahman, FASEB J. 7, 572 (1993).
35. Y Romsicki and F J. Sharom, Biochemistry 38, 6887 (1999).
36. A. V. Kabanov, E. V. Batrakova, and V. Y Alakhov, Adv. Drug Del. Rev. 54, 759 (2002).
37. A. Nori, K. D. Jensen, M. Tijerina, P. Kopeckova, and J. Kopecek, J. Controlled Release 91, 53 (2003).
38. H. L. Wong, R. Bendayan, A. M. Rauth, H. Y Xue, K. Babakhanian, and X. Y Wu, J. Pharmacol. Exp. Ther. 317, 1372 (2006).
39. H. L. Wong, A. M. Rauth, R. Bendayan, J. L. Manias, M. Ramaswamy, Z. Liu, S. Z. Erhan, and X. Y Wu, Pharm. Res. 23, 1574 (2006).
40. K. D. Lee, K. Hong, and D. Papahadjopoulos, Biochim. Biophys. Acta. 1103, 185 (1992).
41. C. E. Soma, C. Dubernet, G. Barratt, F. Nemati, M. Appel, S. Benita, and P. Couvreur, Pharm. Res. (NY) 16, 1710 (1999).
42. S. V. Ambudkar, C. Kimchi-Sarfaty, Z. E. Sauna, and M. M. Gottesman, Oncogene 22, 7468 (2003).
43. H. Maeda and Y. Matsumura, Adv. Drug Deliv. Rev. (2010), in press.
44. PMID: 20457195 [PubMed - as supplied by publisher].
45. R. K. Jain, J. Natl. Cancer Inst. 81, 570 (1989).
46. S. K. Hobbs, W. L. Monsky, F Yuan, W G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain, Proc. Natl. Acad. Sci. 95, 4607 (1998).